Who
Julie L. Gerberding
Director
Company insider
Files Form 4 as: Director, McKesson; Director, HilleVax; Director, Cerner; EVP, Chief Patient Officer, Merck & Company.
In numbers
- Trades disclosed
- 75
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $31.8M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 23 Feb 2015
- Last trade
- 22 Jul 2026
- Last filed
- 23 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jul 2026filed 23 Jul 2026 | MCK McKessonoption or derivative · Health Care Distribution | SEC FORM 4 Code A | —277 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | MCK McKessonoption or derivative · Health Care Distribution | SEC FORM 4 Code A | —277 at $0.00 | filing |
| 17 Sep 2025filed 17 Sep 2025 | HilleVax | SEC FORM 4 Code U | —59,224 | filing |
| 30 Jul 2025filed 31 Jul 2025 | MCK McKessonoption or derivative · Health Care Distribution | SEC FORM 4 Code A | —301 at $0.00 | filing |
| 23 Jun 2025filed 25 Jun 2025 | HilleVax | SEC FORM 4 Code A | —17,199 at $0.00 | filing |
| 7 Feb 2025filed 10 Feb 2025 | MCK McKessonoption or derivative · Health Care Distribution | SEC FORM 4 Code A | —176 at $0.00 | filing |
| 6 Jun 2024filed 30 Apr 2025 | HilleVaxoption or derivative | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | HilleVaxoption or derivative | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 19 Aug 2022filed 23 Aug 2022 | HilleVaxoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | Cerner | SEC FORM 4 Code U | $1.4M15,032 at $95.00 | filing |
| 24 Feb 2022filed 28 Feb 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code A | $702K9,550 at $73.51 | filing |
| 1 Nov 2021filed 3 Nov 2021 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —35,287 at $0.00 | filing |
| 1 Nov 2021filed 3 Nov 2021 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —30,175 at $0.00 | filing |
| 1 Nov 2021filed 3 Nov 2021 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —19,394 at $0.00 | filing |
| 1 Nov 2021filed 3 Nov 2021 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,414 at $0.00 | filing |
| 1 Nov 2021filed 3 Nov 2021 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | —35,287 at $0.00 | filing |
| 1 Nov 2021filed 3 Nov 2021 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | —30,175 at $0.00 | filing |
| 1 Nov 2021filed 3 Nov 2021 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | —19,394 at $0.00 | filing |
| 1 Nov 2021filed 3 Nov 2021 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | —11,414 at $0.00 | filing |
| 1 Nov 2021filed 3 Nov 2021 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $8.5M96,270 at $87.91 | filing |
News
Merck's KEYTRUDA Plus Padcev Wins EU Approval For Muscle-Invasive Bladder CancerMRK · rttnews.com · 21 Oct 2026Contrasting Merck & Co., Inc. (NYSE:MRK) and ABVC BioPharma (NASDAQ:ABVC)MRK · themarketsdaily.com · 21 Oct 2026Merck (MRK) Has New Cancer Treatments. Can They Outgrow the Keytruda Patent Cliff?MRK · insidermonkey.com · 20 Oct 2026
0 headlines in the last 90 days name Julie L. Gerberding; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.